

For Public Release

NZX Limited
Wellington

15 December 2023

Notification of Issue of Securities

Please find attached the Capital Change Notice regarding the issue of ordinary shares.

This notice relates to CBD's recent Rights Issue.

The Rights Issue raised a total of \$1,390,154.93 through the issue of 9,929,600 new ordinary fully paid shares.

-ENDS-

For further information visit www.cannasouth.co.nz or contact:

Mark Lucas

CEO / Executive Director
Email: mark.lucas@cannasouth.co.nz
Mobile: 021 484 649

Tony Ho

Chairman, Cannasouth Limited
Email: tony.ho@cannasouth.co.nz
Mobile: +61 (0)417 345 839

About Cannasouth Limited

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products are produced under GMP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd and Eqalis Group New Zealand Ltd.

For video footage, photos and logos please visit: <https://www.cannasouth.co.nz/about/media/>